FARIBORZ SHAMS: Open Payments
NPI 1063421865 · ANAHEIM, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$9,347 in 37 payments from 17 companies in 2025. Trend: 2023 $3,128 · 2024 $21,243 · 2025 $9,347
Consulting: $6,525Honoraria: $1,250Food & beverage: $1,151Travel & lodging: $421
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 10 | $6,264 |
| Becton, Dickinson and Company | 2 | $2,250 |
| Otsuka America Pharmaceutical, Inc. | 2 | $156 |
| Janssen Biotech, Inc. | 1 | $149 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $77 |
| ACADIA Pharmaceuticals Inc | 2 | $66 |
| Lundbeck LLC | 3 | $57 |
| Alkermes, Inc. | 2 | $45 |
| AstraZeneca Pharmaceuticals LP | 2 | $43 |
| Lilly USA, LLC | 2 | $40 |
Products named: INGREZZA, HemoSphere, RYBREVANT, CAPLYTA, REXULTI, JARDIANCE, ARISTADA, DAYBUE.
Industry payments across CA — which companies pay providers there.
